Cardiovascular Events
Showing 1 - 25 of >10,000
Inclisiran on Major Adverse Cardiovascular Events in French
Not yet recruiting
- Atherosclerotic Cardiovascular Disease
- Inclisiran sodium
- +3 more
- (no location specified)
Jul 26, 2023
Frailty on Cardiovascular Events and Mortality in COPD.
Not yet recruiting
- Role of Frailty in COPD
- Assessment of cardiovascular events, cardiovascular mortality, all-cause mortality, and mortality due to COPD at 12 and 24 months
- (no location specified)
Jun 19, 2023
Cardiovascular Diseases, Uric Acid Trial (Allopurinol 200 mg, Optional intervention)
Not yet recruiting
- Cardiovascular Diseases
- Uric Acid
- Allopurinol 200 mg
- Optional intervention
- (no location specified)
Jul 5, 2023
Suspicion of Cardiovascular Events on Immunecheckpoint
Recruiting
- Cancer
- +3 more
- No intervention for research purposes only
-
Paris, FranceIntitut Mutualiste Montsouris
Mar 23, 2023
Cardiovascular Diseases Trial in Nassau (Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte))
Recruiting
- Cardiovascular Diseases
- Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)
-
Nassau, The Bahamas, BahamasThe Partners Clinical Research Centre at The Medical Pavilion
Oct 17, 2023
Obesity Trial (Naltrexone-Bupropion (NB) Combination, Placebo)
Not yet recruiting
- Obesity
- Naltrexone-Bupropion (NB) Combination
- Placebo
- (no location specified)
Oct 18, 2023
Coronary Artery Disease Trial in Sacramento (device, behavioral, other)
Recruiting
- Coronary Artery Disease
- LiveCare
- +2 more
-
Sacramento, CaliforniaUniversity of California, Davis Medical Center Division of Cardi
Oct 27, 2023
Ferroptosis in COPD COPD With/Without Risk of Cardiovascular
Recruiting
- COPD Exacerbation
- Non-interventional study
-
Santander, Cantabria, SpainHospital Universitario Marqués de Valdecilla
Oct 25, 2023
Diabetes, Type 2, Major Adverse Cardiac Events Trial in Hangzhou (CGM)
Not yet recruiting
- Diabetes Mellitus, Type 2
- Major Adverse Cardiac Events
- CGM
-
Hangzhou, Chinathe Second Affiliated Hospital Zhejiang University Schoolof Medi
Sep 23, 2023
Primary Cardiovascular Events Using the Multimarker Approach
Completed
- Cardiovascular Diseases
- +4 more
- measurement of multiple biomarkers
- (no location specified)
Jan 19, 2023
Major Adverse Cardiovascular Events in Coronary Artery Disease
Completed
- Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease
-
Jinan, Shandong, ChinaYuguo Chen
Sep 20, 2022
Primary Prevention of Atherosclerotic Cardiovascular Disease Trial (Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran)
Not yet recruiting
- Primary Prevention of Atherosclerotic Cardiovascular Disease
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Placebo in 1.5ml
- (no location specified)
Feb 13, 2023
Myocardial Disease Trial in Milano, Roma (Sample blood)
Active, not recruiting
- Myocardial Disease
- Sample blood
-
Milano, Italy
- +1 more
Feb 17, 2023
Cardiovascular Events in Patients With Schizophrenia
Recruiting
- Schizophrenia
-
Shanghai, Shanghai, ChinaShanghai Mental Health Center
Aug 11, 2022
Arteriosclerosis, Hypercholesterolaemia Trial (MK-0616, Placebo)
Not yet recruiting
- Arteriosclerosis
- Hypercholesterolaemia
- MK-0616
- Placebo
- (no location specified)
Aug 17, 2023
Triglyceride-Glucose Index on Cardiovascular Outcomes in
Not yet recruiting
- Major Cardiovascular Events
- Triglyceride glucose index TyG
- (no location specified)
Oct 6, 2023
Cardiovascular Diseases Trial in Shatin (TQJ230, Placebo)
Active, not recruiting
- Cardiovascular Diseases
- TQJ230
- Placebo
-
Shatin, Hong KongThe Chinese University of Hong Kong
Sep 16, 2022
French National Observatory Tracking Viral Myocarditis:
Completed
- Myocarditis
- +2 more
-
Paris, FranceBichat
Sep 15, 2022
Diabetes, Type 2, PreDiabetes, Metabolic Syndrome Trial (The Cleerly CAD Staging System)
Not yet recruiting
- Diabetes Mellitus, Type 2
- +2 more
- The Cleerly CAD Staging System
- (no location specified)
Oct 31, 2023
Diabetes, Type 2 Trial (Semaglutide Oral Tablet, Placebo oral tablet)
Not yet recruiting
- Diabetes Mellitus, Type 2
- Semaglutide Oral Tablet
- Placebo oral tablet
- (no location specified)
Jul 1, 2022
Acute Coronary Syndrome, Hyperlipidemias, Percutaneous Coronary Intervention Trial in Nanjing (Placebo plus high-intensity
Not yet recruiting
- Acute Coronary Syndrome
- +3 more
- Placebo plus high-intensity statin
- PCSK 9 Inhibitor plus high-intensity statin
-
Nanjing, Jiangsu, ChinaNanjing First Hospital
Aug 1, 2022
Prediction of Cardiovascular Events
Recruiting
- Cardiovascular Diseases
- additional blood samples
-
Toulouse, FranceUniversity Hospital Toulouse
May 17, 2022
Anticoagulant Drug Intervention on Postoperative MALE and MACE
Recruiting
- Anticoagulant Drugs
- +2 more
- anticoagulant or antiplatelet drugs
-
Hangzhou, None Selected, ChinaFirst Affiliated Hospital of Zhejiang University
May 8, 2023
Cardiovascular Events by Platelet FcGammaRIIa
Recruiting
- STEMI
- NSTEMI
-
Burlington, VermontUniversity of Vermont
Apr 28, 2022
s on Leukocyte Distribution, Monocyte Function and Platelet
Recruiting
- Arteriosclerosis
- +3 more
-
Düsseldorf, GermanyUniversity-Hospital Düsseldorf Division of Cardiology, Pulmonary
Aug 2, 2023